BR9809819A - Compostos e métodos para a inibição da expressão de vcam-1 - Google Patents

Compostos e métodos para a inibição da expressão de vcam-1

Info

Publication number
BR9809819A
BR9809819A BR9809819-5A BR9809819A BR9809819A BR 9809819 A BR9809819 A BR 9809819A BR 9809819 A BR9809819 A BR 9809819A BR 9809819 A BR9809819 A BR 9809819A
Authority
BR
Brazil
Prior art keywords
expression
methods
compounds
vcam
inhibiting vcam
Prior art date
Application number
BR9809819-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Patricia K Somers
Lee K Hoong
Charles Q Meng
Original Assignee
Atherogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atherogenics Inc filed Critical Atherogenics Inc
Publication of BR9809819A publication Critical patent/BR9809819A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/21—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with the sulfur atom of the thio group bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/56—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/66—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfo, esterified sulfo or halosulfonyl groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BR9809819-5A 1997-05-14 1998-05-14 Compostos e métodos para a inibição da expressão de vcam-1 BR9809819A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4702097P 1997-05-14 1997-05-14
PCT/US1998/009781 WO1998051662A2 (en) 1997-05-14 1998-05-14 Compounds and methods for the inhibition of the expression of vcam-1

Publications (1)

Publication Number Publication Date
BR9809819A true BR9809819A (pt) 2001-09-18

Family

ID=21946634

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9809793-8A BR9809793A (pt) 1997-05-14 1998-05-14 Monoésteres de probucol para o tratamento de doença inflamatória e cardiovascular
BR9809819-5A BR9809819A (pt) 1997-05-14 1998-05-14 Compostos e métodos para a inibição da expressão de vcam-1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR9809793-8A BR9809793A (pt) 1997-05-14 1998-05-14 Monoésteres de probucol para o tratamento de doença inflamatória e cardiovascular

Country Status (25)

Country Link
US (9) US6121319A (enExample)
EP (2) EP0981343B1 (enExample)
JP (4) JP2001524986A (enExample)
KR (5) KR20070008725A (enExample)
CN (7) CN1275596C (enExample)
AT (3) ATE356113T1 (enExample)
AU (2) AU747801C (enExample)
BR (2) BR9809793A (enExample)
CA (3) CA2292388C (enExample)
CY (1) CY1107645T1 (enExample)
CZ (4) CZ301985B6 (enExample)
DE (3) DE69837295T2 (enExample)
DK (2) DK1464639T3 (enExample)
EA (5) EA010183B1 (enExample)
ES (3) ES2241139T3 (enExample)
HU (2) HU226611B1 (enExample)
ID (2) ID23877A (enExample)
IL (7) IL132797A0 (enExample)
NO (3) NO327603B1 (enExample)
NZ (2) NZ528906A (enExample)
PL (2) PL207885B1 (enExample)
PT (1) PT1464639E (enExample)
SK (4) SK286392B6 (enExample)
TR (2) TR199902803T2 (enExample)
WO (2) WO1998051662A2 (enExample)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670398B2 (en) * 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
CN1275596C (zh) * 1997-05-14 2006-09-20 阿特罗吉尼克斯公司 普罗布考单酯在制备用于治疗心血管疾病和炎性疾病的药物中的应用
US6852878B2 (en) 1998-05-14 2005-02-08 Atherogenics, Inc. Thioketals and thioethers for inhibiting the expression of VCAM-1
JP2002511878A (ja) * 1997-07-01 2002-04-16 アセロジエニクス・インコーポレイテツド 抗酸化剤による過増殖状態の治療の増強
JP2001517617A (ja) 1997-09-24 2001-10-09 ノヴァ モレキュラー インク． 神経変性疾患の治療を目的としてａｐｏｅレベルを増加させる方法
US6887712B1 (en) 1998-11-09 2005-05-03 Atherogenics, Inc. Methods and compositions to lower plasma cholesterol levels
CO5170498A1 (es) * 1999-05-28 2002-06-27 Abbott Lab Biaril sulfonamidas son utiles como inhibidores de proliferacion celular
US7361684B2 (en) * 1999-06-28 2008-04-22 Massachusetts Institute Of Technology Screening of compounds for treatment of atherosclerosis and heart attack
US6403637B1 (en) * 1999-08-09 2002-06-11 Univ Saint Louis Methods of modulating matrix metalloproteinase activity and uses thereof
AU4765101A (en) * 2000-03-21 2001-10-03 Atherogenics Inc Thioketals and thioethers for inhibiting the expression of vcam-1
JP2003530383A (ja) * 2000-04-11 2003-10-14 アセロジエニクス・インコーポレイテツド 血漿ｈｄｌコレステロールレベルを上昇させ、ｈｄｌ機能性を向上させる化合物および方法
US6323359B1 (en) * 2000-05-02 2001-11-27 Salsbury Chemicals, Inc. Process for preparing probucol derivatives
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
NZ523443A (en) * 2000-06-20 2004-11-26 Atherogenics Inc 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders
AUPQ872800A0 (en) * 2000-07-12 2000-08-03 Heart Research Institute, The Compositions and methods for treating cardiovascular disorders
BR0115474A (pt) 2000-11-17 2006-01-31 Idenix Cayman Ltd Composição e método para inibição da transmissão de hiv que usam 6-benzil-4-oxopirimidinas substituìdas aplicada por via tópica
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
RS20100015A (sr) 2001-01-26 2010-12-31 Schering Corporation Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
HU230435B1 (hu) 2001-01-26 2016-06-28 Merck Sharp & Dohme Corp Szubsztituált azetidinon vegyületek alkalmazása szitoszterinémia kezelésére
EP1385501A2 (en) * 2001-04-11 2004-02-04 Atherogenics, Inc. Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
CA2460340C (en) 2001-09-21 2011-02-15 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
WO2003039231A2 (en) * 2001-10-25 2003-05-15 Atherogenics, Inc. Compounds and methods for treating transplant rejection
JP2006506314A (ja) * 2001-11-09 2006-02-23 アセロジエニクス・インコーポレイテツド 心血管疾患の逆転及び予防方法
JP2005516941A (ja) 2001-12-19 2005-06-09 アセロジエニクス・インコーポレイテツド カルコン誘導体及び疾患を治療するためのそれらの使用
US6939554B2 (en) * 2002-02-05 2005-09-06 Michigan Biotechnology Institute Antimicrobial polymer
ITMI20020597A1 (it) * 2002-03-22 2003-09-22 Nicox Sa Derivati del probucolo
US7208467B2 (en) 2002-06-07 2007-04-24 Monty Krieger Lipid-altering compositions for the treatment of infertility
US6960683B2 (en) * 2002-07-12 2005-11-01 Atherogenics, Inc. Salt forms of poorly soluble probucol esters and ethers
US20050163821A1 (en) * 2002-08-02 2005-07-28 Hsing-Wen Sung Drug-eluting Biodegradable Stent and Delivery Means
US20040110803A1 (en) * 2002-09-13 2004-06-10 Hossein Dovlatabadi Methods and compositions for the use of D-malic acid to decrease serum triglyceride, cholesterol and lipoprotein levels
CA2501685A1 (en) * 2002-10-08 2004-04-22 Massachusetts Institute Of Technology Compounds for modulation of cholesterol transport
MXPA05004811A (es) 2002-11-06 2005-07-22 Schering Corp Inhibidores de absorcion de colesterol para el tratamiento de trastornos autoinmunes.
AU2002953533A0 (en) * 2002-12-24 2003-01-16 Arthron Limited Fc receptor modulating compounds and compositions
SG142207A1 (en) * 2003-01-13 2008-05-28 Atherogenics Inc Process of preparing esters and ethers of probucol and derivatives thereof
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
MXPA05009502A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
MXPA05009501A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
MXPA05009848A (es) * 2003-03-17 2005-12-06 Japan Tobacco Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia del ester de colesterilo.
US7173129B2 (en) 2003-06-06 2007-02-06 Athero Genics, Inc. Sulfonamide-substituted chalcone derivatives and their use to treat diseases
WO2005025492A2 (en) * 2003-07-07 2005-03-24 Emory University Novel compositions, pharmaceutical compositions, and methods for the treatment and prevention of heart disease
US20050026879A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050074443A1 (en) * 2003-10-03 2005-04-07 Treadwell Benjamin V. Methods of attenuating autoimmune disease and compositions useful therefor
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
WO2005039596A1 (en) * 2003-10-17 2005-05-06 Amylin Pharmaceuticals, Inc. Silyl phenols for promoting vascular health
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
CA2546495C (en) * 2003-11-14 2012-10-09 Temple University - Of The Commonwealth System Of Higher Education Alpha, beta-unsaturated sulfoxides for treating proliferative disorders
EP1689707A1 (en) * 2003-11-25 2006-08-16 Novo Nordisk A/S Novel compounds for the treatment of obesity
US20060025481A1 (en) * 2004-02-09 2006-02-02 Strange Matthew L Process for preparation of probucol derivatives and polymorphic forms thereof
US7294736B2 (en) * 2004-04-09 2007-11-13 Cambrex Charles City, Inc. Process for preparation of probucol derivatives
WO2005102323A2 (en) * 2004-04-20 2005-11-03 Atherogenics, Inc. Process of preparing esters and ethers of probucol and derivatives thereof
WO2005112914A2 (en) * 2004-04-20 2005-12-01 Atherogenics, Inc. Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease
US20050272770A1 (en) * 2004-04-29 2005-12-08 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20050282883A1 (en) * 2004-04-29 2005-12-22 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7199126B2 (en) * 2004-04-29 2007-04-03 Pharmix Corporation Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7183285B2 (en) * 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
WO2006004903A2 (en) * 2004-06-28 2006-01-12 Atherogenics, Inc. 1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
JP2008505097A (ja) * 2004-07-01 2008-02-21 アセロジエニクス・インコーポレイテツド 糖尿病性血管疾患を治療するための化合物および方法
JP2008514718A (ja) * 2004-09-29 2008-05-08 シェーリング コーポレイション 置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ
US20060111436A1 (en) * 2004-11-23 2006-05-25 John Griffin Compositions and treatments for modulating kinase and/or HMG-CoA reductase
CN101115726A (zh) 2004-12-03 2008-01-30 先灵公司 作为cb1拮抗剂的取代哌嗪
WO2006063408A1 (en) * 2004-12-17 2006-06-22 Stocker Ronald O Compositions and methods for treating cardiovascular disorders
US7345191B2 (en) * 2005-02-26 2008-03-18 Cambrex Charles City, Inc. Process for preparation of probucol derivatives
CA2606414A1 (en) 2005-04-21 2006-11-02 Atherogenics, Inc. Process for the separation of probucol derivatives
US20070015779A1 (en) * 2005-04-29 2007-01-18 John Griffin Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US20060269579A1 (en) * 2005-05-25 2006-11-30 Musculoskeletal Research Llc Compositions for treating osteoarthritis
US7767710B2 (en) * 2005-05-25 2010-08-03 Calosyn Pharma, Inc. Method for treating osteoarthritis
US7897601B2 (en) 2006-01-18 2011-03-01 Intervet, Inc. Cannabinoid receptor modulators
WO2007142581A1 (en) * 2006-06-07 2007-12-13 Astrazeneca Ab Combination product for the treatment or prevention of dyslipidaemia
BRPI0809423A2 (pt) 2007-03-26 2014-09-09 Salutria Pharmaceuticals Llc Usos e composições de derivados de probucol para o tratamento de diabetes
WO2008118946A1 (en) * 2007-03-27 2008-10-02 Atherogenics, Inc. Methods and compositions using certain phenolic derivatives for the treatment of diabetes
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
WO2008130718A1 (en) 2007-04-23 2008-10-30 Atherogenics, Inc. Sulfonamide containing compounds for treatment of inflammatory disorders
WO2009002263A1 (en) * 2007-06-26 2008-12-31 Astrazeneca Ab Process for isolating mono-carboxy substituted probucol derivates
EP2548874A3 (en) * 2007-06-28 2013-05-15 Intervet International B.V. Substituted piperazines as CB1 antagonists
WO2009005671A2 (en) * 2007-06-28 2009-01-08 Schering Corporation Substituted piperazines as cb1 antagonists
WO2009042854A1 (en) * 2007-09-26 2009-04-02 Musculoskeletal Research Llc Ion-channel regulator compositions and methods of using same
US9656019B2 (en) 2007-10-02 2017-05-23 Medimop Medical Projects Ltd. Apparatuses for securing components of a drug delivery system during transport and methods of using same
US9345836B2 (en) 2007-10-02 2016-05-24 Medimop Medical Projects Ltd. Disengagement resistant telescoping assembly and unidirectional method of assembly for such
US10420880B2 (en) 2007-10-02 2019-09-24 West Pharma. Services IL, Ltd. Key for securing components of a drug delivery system during assembly and/or transport and methods of using same
US7967795B1 (en) 2010-01-19 2011-06-28 Lamodel Ltd. Cartridge interface assembly with driving plunger
BRPI0817907B8 (pt) 2007-10-02 2021-06-22 Lamodel Ltd aparelho para administrar uma substância a um indivíduo
CA2703203C (en) 2007-10-22 2015-12-15 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
JP5669729B2 (ja) * 2008-05-13 2015-02-12 ジェンメディカ・セラピューティックス・ソシエダッド・リミターダＧｅｎｍｅｄｉｃａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓｌ 代謝性障害を治療するのに有用なサリチレートコンジュゲート
EP2297117B1 (en) 2008-05-19 2012-10-31 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
US8822480B2 (en) 2008-07-16 2014-09-02 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and use thereof as GPR119 modulators
US9393369B2 (en) 2008-09-15 2016-07-19 Medimop Medical Projects Ltd. Stabilized pen injector
US12097357B2 (en) 2008-09-15 2024-09-24 West Pharma. Services IL, Ltd. Stabilized pen injector
US20100145305A1 (en) * 2008-11-10 2010-06-10 Ruth Alon Low volume accurate injector
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
US8410122B2 (en) 2008-12-23 2013-04-02 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and methods of use thereof
JP2012513469A (ja) 2008-12-23 2012-06-14 シェーリング コーポレイション ピリミジン誘導体及びその使用法
WO2010075273A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
US8152779B2 (en) * 2008-12-30 2012-04-10 Medimop Medical Projects Ltd. Needle assembly for drug pump
CA2755069A1 (en) * 2009-03-16 2010-09-23 Genmedica Therapeutics Sl Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
CN102421424A (zh) * 2009-03-16 2012-04-18 根梅迪卡治疗公司 用于治疗代谢性疾病的组合疗法
CN105859639A (zh) 2009-03-18 2016-08-17 雷斯韦洛吉克斯公司 新的抗炎剂
AR076024A1 (es) 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
EP2414348B1 (en) 2009-04-03 2013-11-20 Merck Sharp & Dohme Corp. Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders
JP5830013B2 (ja) 2009-05-18 2015-12-09 テロメレイズ アクティベイション サイエンシズ，インコーポレーテッド テロメラーゼ活性を増大させるための組成物および方法
US8157769B2 (en) * 2009-09-15 2012-04-17 Medimop Medical Projects Ltd. Cartridge insertion assembly for drug delivery system
US10071196B2 (en) 2012-05-15 2018-09-11 West Pharma. Services IL, Ltd. Method for selectively powering a battery-operated drug-delivery device and device therefor
US10071198B2 (en) 2012-11-02 2018-09-11 West Pharma. Servicees IL, Ltd. Adhesive structure for medical device
AU2010313469A1 (en) 2009-10-29 2012-06-07 Merck Sharp & Dohme Corp. Bridged Bicyclic Piperidine Derivatives and methods of use thereof
WO2011062889A1 (en) 2009-11-23 2011-05-26 Schering Corporation Pyrimidine ether derivatives and methods of use thereof
EP2504010A4 (en) 2009-11-23 2013-04-17 Merck Sharp & Dohme Fused Bicyclic Pyrimidine Derivatives and Methods of Use Therefor
EP2503887B1 (en) 2009-11-24 2016-01-06 Merck Sharp & Dohme Corp. Substituted biaryl derivatives and methods of use thereof
US8348898B2 (en) 2010-01-19 2013-01-08 Medimop Medical Projects Ltd. Automatic needle for drug pump
EP2569031B1 (en) 2010-05-10 2017-10-11 Medimop Medical Projects Ltd. Low volume accurate injector
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
USD702834S1 (en) 2011-03-22 2014-04-15 Medimop Medical Projects Ltd. Cartridge for use in injection device
US9072827B2 (en) 2012-03-26 2015-07-07 Medimop Medical Projects Ltd. Fail safe point protector for needle safety flap
US9421323B2 (en) 2013-01-03 2016-08-23 Medimop Medical Projects Ltd. Door and doorstop for portable one use drug delivery apparatus
SG11201508027PA (en) 2013-02-28 2015-11-27 Harvard College Methods and compositions for mobilizing stem cells
US9011164B2 (en) 2013-04-30 2015-04-21 Medimop Medical Projects Ltd. Clip contact for easy installation of printed circuit board PCB
US10293120B2 (en) 2015-04-10 2019-05-21 West Pharma. Services IL, Ltd. Redundant injection device status indication
US10149943B2 (en) 2015-05-29 2018-12-11 West Pharma. Services IL, Ltd. Linear rotation stabilizer for a telescoping syringe stopper driverdriving assembly
CN107683158B (zh) 2015-06-04 2021-05-14 麦迪麦珀医疗工程有限公司 用于药物释放装置的筒插入
US9987432B2 (en) 2015-09-22 2018-06-05 West Pharma. Services IL, Ltd. Rotation resistant friction adapter for plunger driver of drug delivery device
US10086145B2 (en) 2015-09-22 2018-10-02 West Pharma Services Il, Ltd. Rotation resistant friction adapter for plunger driver of drug delivery device
US10576207B2 (en) 2015-10-09 2020-03-03 West Pharma. Services IL, Ltd. Angled syringe patch injector
CN108472438B (zh) 2015-10-09 2022-01-28 西医药服务以色列分公司 至预填充的流体储存器的弯曲流体路径附加装置
EP3405227B1 (en) 2016-01-21 2020-06-17 West Pharma. Services Il, Ltd. Force containment in an automatic injector
CN109310816B (zh) 2016-01-21 2020-04-21 西医药服务以色列有限公司 针插入和缩回机构
JP6885960B2 (ja) 2016-01-21 2021-06-16 ウェスト ファーマ サービシーズ イスラエル リミテッド 視覚的インジケータを有する薬剤デリバリデバイス
US11389597B2 (en) 2016-03-16 2022-07-19 West Pharma. Services IL, Ltd. Staged telescopic screw assembly having different visual indicators
US10376647B2 (en) 2016-03-18 2019-08-13 West Pharma. Services IL, Ltd. Anti-rotation mechanism for telescopic screw assembly
JP6957525B2 (ja) 2016-06-02 2021-11-02 ウェスト ファーマ サービシーズ イスラエル リミテッド ３つの位置による針の退避
US9650332B1 (en) * 2016-06-16 2017-05-16 Yong Xu Prodrug of probucol and method for preparing the same
JP7059251B2 (ja) 2016-08-01 2022-04-25 ウェスト ファーマ サービシーズ イスラエル リミテッド ドアの半閉じを防止するスプリング
WO2018026387A1 (en) 2016-08-01 2018-02-08 Medimop Medical Projects Ltd. Anti-rotation cartridge pin
CN106905208B (zh) * 2017-02-27 2018-09-07 江西瑞雅药业有限公司 普罗布考前药及其制备方法和药物组合物
US11819666B2 (en) 2017-05-30 2023-11-21 West Pharma. Services IL, Ltd. Modular drive train for wearable injector
WO2019126421A1 (en) 2017-12-22 2019-06-27 West Pharma. Services Il., Ltd. Injector usable with different dimension cartridges
CN108299263B (zh) 2018-01-30 2020-12-01 北京德默高科医药技术有限公司 一种普罗布考衍生物及其制备方法与应用
WO2022236107A1 (en) * 2021-05-07 2022-11-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for treating allergies and inflammatory conditions

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3179701A (en) * 1962-05-14 1965-04-20 Shell Oil Co (3, 5-dialkyl-4-hydroxyphenyl) (3, 5-dialkyl-4-hydroxybenzyl) sulfides
US4115590A (en) * 1964-02-26 1978-09-19 Ethyl Corporation Binuclear phenols for reducing plasma lipid levels
GB1136539A (en) * 1966-12-13 1968-12-11 Uniroyal Inc Phenolic sulphides
US3485843A (en) * 1967-05-11 1969-12-23 Dow Chemical Co Piperazine adducts of ketone mercaptoles
GB1199871A (en) * 1967-05-11 1970-07-22 Consolidation Coal Co Improvements in or relating to Sulfur-Containing Bisphenols
GB1148550A (en) * 1967-12-02 1969-04-16 Uniroyal Inc Substituted benzylphenyl sulfides and their use as antioxidants
US3479407A (en) * 1968-11-06 1969-11-18 Consolidation Coal Co Sulfurization of 2,6-di-tert-butylphenol
US3576883A (en) * 1969-06-30 1971-04-27 Consolidation Coal Co Alkylidenedithiobisphenols
DE2104524C3 (de) 1970-09-16 1980-08-07 Veb Kombinat Umformtechnik Herbert Warnke Erfurt, Ddr 5000 Erfurt Hydraulische Überlastsicherung
FR2130975A5 (en) * 1971-03-29 1972-11-10 Aries Robert Bis(4-(phenoxyalkanoyloxy)-phenylthio)alkanes - hypolipemics hypocholesterolemics
FR2133024A5 (en) * 1971-04-06 1972-11-24 Aries Robert Bis-(4-nicotinoyloxyphenylthio) propanes - with hypocholesterolaemic and hypolipaemic activity
FR2134810A5 (en) * 1971-04-21 1972-12-08 Aries Robert Bis-(3-alkyl-5-t-alkyl-4-(thiazole-5-carboxy)phenylthio) alcanes - - with hypocholesterolaemic and hypolipaemic activity
FR2140769A5 (en) * 1971-06-07 1973-01-19 Aries Robert Benzofuryloxy alkanoic derivs of probucol - hypocholesterolemic and hypolipemic agents
FR2140771A5 (en) * 1971-06-07 1973-01-19 Aries Robert Tetralinyl phenoxy alkanoic esters - of bis hydroxyphenylthio alkanes, hypolipemics etc
FR2168137A1 (en) * 1972-01-17 1973-08-31 Dynachim Sarl Bis 4-hydroxyphenylthioalkane esters - with hypocholesterolaemic and hypolipaemic activities
JPS4975552A (enExample) * 1972-11-20 1974-07-20
US3952064A (en) * 1973-03-12 1976-04-20 Crown Zellerbach Corporation Process for producing mercaptophenols
US4029812A (en) * 1976-02-18 1977-06-14 The Dow Chemical Company Novel hypolipidemic 2-(3,5-di-tert-butyl-4-hydroxyphenyl)thio carboxamides
JPS52125170A (en) * 1976-04-12 1977-10-20 Yoshitomi Pharmaceut Ind Ltd Pyridine derivatives
US4968514A (en) * 1984-12-11 1990-11-06 Forbes Polytech, Inc. Beer bottle with fully reacted thermoplastic polyurethane crown capliner
AU584669B2 (en) * 1985-02-04 1989-06-01 G.D. Searle & Co. Novel disubstituted 4-hydroxyphenylthio anilides
US4679520A (en) 1985-06-10 1987-07-14 Harken Olaf T Mainsail reefing and furling device and method
DE3530256A1 (de) 1985-08-23 1987-02-26 Merrell Dow Pharma Verwendung von probucol bei der behandlung von herzarrhythmie
US4755524A (en) * 1986-01-31 1988-07-05 G. D. Searle & Co. Novel phenolic thioethers as inhibitors of 5-lipoxygenase
DE3625279A1 (de) 1986-07-25 1988-02-04 Merrell Dow Pharma Verwendung von probucol zur vorbeugung und behandlung von erkrankungen des herzens
DE3869202D1 (de) * 1987-03-17 1992-04-23 Merrell Dow Pharma Alkylidendithiobis (substituierte) phenolen zur hemmung der freisetzung von interleukin-1 und zur linderung von interleukin-1 vermittelten krankheiten.
US4975467A (en) 1987-03-17 1990-12-04 Merrell Dow Pharmaceuticals Inc. Method of inhibiting interleukin-1 release and alleviating interleukin-1 mediated conditions
US4752616A (en) * 1987-06-29 1988-06-21 E. R. Squibb & Sons, Inc. Arylthioalkylphenyl carboxylic acids, compositions containing same and method of use
US5066822A (en) 1987-11-13 1991-11-19 Riker Laboratories, Inc Di-t-butylphenols substituted by an alkoxy or benzyloxy group or a benzylthio group
US4968710A (en) 1987-11-13 1990-11-06 Riker Laboratories, Inc. Substituted di-t-butylphenols and anti-allergic use thereof
NZ226621A (en) * 1987-11-13 1991-12-23 Riker Laboratories Inc Di-tert butyl phenols substituted by alkoxy, benzyloxy, or benzylthio groups; pharmaceutical compositions containing them
CH675422A5 (enExample) 1988-03-31 1990-09-28 Symphar Sa
JP2754039B2 (ja) 1988-06-24 1998-05-20 塩野義製薬株式会社 ジ―ｔｅｒｔ―ブチルヒドロキシフェニルチオ誘導体
JP2627003B2 (ja) * 1989-01-25 1997-07-02 塩野義製薬株式会社 ジーｔｅｒｔ―ブチルヒドロキシフェニルチオ誘導体
US5527945A (en) 1989-02-10 1996-06-18 Basf Aktiengesellschaft Diphenylheteroalkyl derivatives, the preparation thereof and drugs and cosmetics prepared therefrom
JP3065636B2 (ja) * 1989-06-29 2000-07-17 塩野義製薬株式会社 ［ジ―ｔｅｒｔ―ブチル（ヒドロキシ）フェニルチオ］置換ヒドロキサム酸誘導体
CA2017956A1 (en) * 1989-07-06 1991-01-06 Werner Bollag Use of retinoids
DE3929913A1 (de) 1989-09-08 1991-04-04 Hoechst Ag 4-hydroxytetrahydropyran-2-one sowie die entsprechenden dihydroxycarbonsaeurederivate, salze und ester, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate sowie vorprodukte
US5115250A (en) * 1990-01-12 1992-05-19 Hewlett-Packard Company Wiper for ink-jet printhead
US5112870A (en) 1990-05-09 1992-05-12 Merrell Dow Pharmaceuticals Inc. Bis(alkyl-substituted-4-hydroxyphenylthio)alkane analogs as inhibitors of cataractogenesis
US5061734A (en) 1990-05-09 1991-10-29 Merrell Dow Pharmaceuticals Inc. Bis(alkyl-substituted-4-hydroxyphenylthio)alkane analogs as inhibitors of cataractogenesis
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
US5155250A (en) * 1990-07-05 1992-10-13 Merrell Dow Pharmaceuticals Inc. 2,6-di-alkyl-4-silyl-phenols as antiatheroscerotic agents
US5085777A (en) * 1990-08-31 1992-02-04 E. I. Du Pont De Nemours And Company Reverse osmosis membranes of polyamideurethane
FR2666583B1 (fr) * 1990-09-06 1994-09-09 Adir Nouveaux derives du spiro [4.5] decane, leur procede de preparation et leurs compositions pharmaceutiques les renfermant.
RU2024509C1 (ru) * 1991-05-07 1994-12-15 Всероссийский научный центр по безопасности биологически активных веществ Производные 9-аминоакридина или их соли с органическими или неорганическими кислотами, проявляющие психотропную, антиамнестическую и липидрегулирующую активность
GB9115951D0 (en) 1991-07-24 1991-09-11 Pfizer Ltd Indoles
EP0625138B1 (de) 1992-02-05 1999-06-02 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Neue amidinderivate, ihre herstellung und verwendung als arzneimittel mit ltb4-antagonistischer wirkung
US5262439A (en) * 1992-04-30 1993-11-16 The Regents Of The University Of California Soluble analogs of probucol
US5310949A (en) 1992-09-02 1994-05-10 Merck & Co., Inc. Cholesterol lowering compounds
GB9220571D0 (en) 1992-09-30 1992-11-11 Ici Plc Quinazoline derivatives
US5380747A (en) * 1992-10-30 1995-01-10 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5807884A (en) * 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5821260A (en) * 1992-10-30 1998-10-13 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5662934A (en) * 1993-01-05 1997-09-02 Najarian; Thomas Compositions and methods for lowering cholesterol while maintaining antioxidant levels
US5585235A (en) 1993-04-13 1996-12-17 Diagnescent Technologies, Inc. Fluorescent assay and method that corrects for spectral interference
FR2704224B1 (fr) * 1993-04-20 1995-08-25 Adir Nouveaux acides et esters phénoxy isobutyriques substitués.
JPH06312978A (ja) * 1993-04-30 1994-11-08 Japan Tobacco Inc ホスホリパーゼａ２阻害活性を有する新規フタルイミド誘導体
US5411741A (en) 1993-07-29 1995-05-02 Zaias; Nardo Method and composition for skin depigmentation
GB9320113D0 (en) 1993-09-29 1993-11-17 Zeneca Ltd Tricyclic derivatives
ATE324113T1 (de) * 1993-12-10 2006-05-15 Merrell Pharma Inc Verwendung von 2,6-dialkyl-4-silyl-phenol derivaten zur behandlung von xanthom
US5426196A (en) 1993-12-22 1995-06-20 Glaxo Inc. Synthesis of diaryl methanes
JPH07328425A (ja) * 1994-06-03 1995-12-19 Toshiba Corp プラズマ化学反応装置
US5693337A (en) 1994-07-13 1997-12-02 Wakamoto Pharmaceutical Co., Ltd. Stable lipid emulsion
US5635514A (en) * 1994-10-25 1997-06-03 G. D. Searle & Company Heteroaralkyl and heteroarylthioalkyl thiophenolic compounds as 5-lipoxgenase inhibitors
US5792787A (en) * 1995-06-07 1998-08-11 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
JPH0959258A (ja) * 1995-08-11 1997-03-04 Ono Pharmaceut Co Ltd グアニジル誘導体
FR2738817B1 (fr) * 1995-09-14 1997-10-17 Adir Nouveaux acides et esters 2,2-dimethyl-omega-phenoxy alcanoiques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO1997015546A1 (fr) * 1995-10-26 1997-05-01 Nippon Shinyaku Co., Ltd. Derives d'acide carboxylique et compositions pharmaceutiques
JP4169368B2 (ja) 1996-01-15 2008-10-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 脈管形成阻害性ピリダジンアミン
US5608095A (en) * 1996-04-30 1997-03-04 Hoechst Marion Roussel, Inc. Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents
KR20000022040A (ko) 1996-06-20 2000-04-25 보오드 오브 리젠츠, 더 유니버시티 오브 텍사스 시스템 약학적 활성 제제를 제공하기 위한 화합물, 방법 및 그의 용도
PT942896E (pt) * 1996-11-20 2003-07-31 Aventis Pharma Inc Fenois e tiofenois substituidos uteis como agentes antioxidantes
AU5959398A (en) 1997-01-09 1998-08-03 Localmed, Inc. Localized intravascular delivery of antioxidant substances for inhibition of restenosis in recanalized blood vessels
GB9705502D0 (en) 1997-03-17 1997-05-07 Univ Wales Swansea The Chlorination or aromatic compounds and catalysts therefor
US6214887B1 (en) 1997-03-24 2001-04-10 Quatro Scientific, Inc. Vascular remodeling agent
CN1275596C (zh) * 1997-05-14 2006-09-20 阿特罗吉尼克斯公司 普罗布考单酯在制备用于治疗心血管疾病和炎性疾病的药物中的应用
US6670398B2 (en) * 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
US6852878B2 (en) * 1998-05-14 2005-02-08 Atherogenics, Inc. Thioketals and thioethers for inhibiting the expression of VCAM-1
JP2002511878A (ja) * 1997-07-01 2002-04-16 アセロジエニクス・インコーポレイテツド 抗酸化剤による過増殖状態の治療の増強
JP2001517617A (ja) 1997-09-24 2001-10-09 ノヴァ モレキュラー インク． 神経変性疾患の治療を目的としてａｐｏｅレベルを増加させる方法
WO1999024400A1 (en) 1997-11-10 1999-05-20 Vyrex Corporation Probucol esters and uses thereof
FR2785284B1 (fr) 1998-11-02 2000-12-01 Galderma Res & Dev Analogues de la vitamine d
DE19850532A1 (de) 1998-11-03 2000-05-04 Nematel Dr Rudolf Eidenschink Bisphenylthio-Verbindungen
EP1137948B1 (en) * 1998-11-09 2006-05-10 Atherogenics, Inc. Methods and compositions to lower plasma cholesterol levels
ATE238287T1 (de) 1998-11-23 2003-05-15 Janssen Pharmaceutica Nv 6-azauracilderivate als il-5 inhibitoren
IL145002A0 (en) 1999-03-10 2002-06-30 Univ Pittsburgh Adipose-derived stem cells and lattices
CA2366857C (en) 1999-03-30 2010-12-14 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
AU2001247649A1 (en) 2000-03-21 2001-10-30 Atherogenics, Inc N-substituted dithiocarbamates for the treatment of biological disorders
AU4765101A (en) * 2000-03-21 2001-10-03 Atherogenics Inc Thioketals and thioethers for inhibiting the expression of vcam-1
US6323359B1 (en) 2000-05-02 2001-11-27 Salsbury Chemicals, Inc. Process for preparing probucol derivatives
EP1385501A2 (en) * 2001-04-11 2004-02-04 Atherogenics, Inc. Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
WO2002092660A2 (en) 2001-05-14 2002-11-21 Omnova Soltions Inc Polymeric surfactants derived from cyclic monomers having pendant fluorinated carbon groups
US7187870B2 (en) * 2003-10-15 2007-03-06 Oewaves, Inc. Tunable balanced opto-electronic filters and applications in opto-electronic oscillators

Also Published As

Publication number Publication date
CN1263522A (zh) 2000-08-16
CA2289851A1 (en) 1998-11-19
CN1496739A (zh) 2004-05-19
CN1496740A (zh) 2004-05-19
CN100453530C (zh) 2009-01-21
NO20032254L (no) 2000-01-10
CZ301302B6 (cs) 2010-01-06
JP2006265257A (ja) 2006-10-05
DE69831566D1 (de) 2006-01-26
TR199902803T2 (xx) 2000-07-21
CA2289851C (en) 2009-03-10
DK1464639T3 (da) 2007-07-09
SK285695B6 (sk) 2007-06-07
ES2283933T3 (es) 2007-11-01
IL164568A0 (en) 2005-12-18
EA010183B1 (ru) 2008-06-30
CN1977836A (zh) 2007-06-13
WO1998051289A3 (en) 1999-05-14
NO995544L (no) 2000-01-10
DE69829966D1 (de) 2005-06-02
JP2002503227A (ja) 2002-01-29
DK0981343T3 (da) 2006-01-30
WO1998051662A2 (en) 1998-11-19
KR100953990B1 (ko) 2010-04-21
US7189870B2 (en) 2007-03-13
US20020188118A1 (en) 2002-12-12
CN1263462A (zh) 2000-08-16
HK1024629A1 (en) 2000-10-20
SK153199A3 (en) 2000-05-16
NZ528906A (en) 2005-06-24
ATE294158T1 (de) 2005-05-15
EA009987B1 (ru) 2008-04-28
US20080214660A1 (en) 2008-09-04
SK286392B6 (sk) 2008-09-05
EP0994853A2 (en) 2000-04-26
US20020169215A1 (en) 2002-11-14
PL207885B1 (pl) 2011-02-28
PL343904A1 (en) 2001-09-10
WO1998051289A2 (en) 1998-11-19
SK153299A3 (en) 2000-05-16
HUP0004592A2 (hu) 2001-06-28
PL194329B1 (pl) 2007-05-31
DE69837295T2 (de) 2007-11-15
SK286674B6 (sk) 2009-03-05
US20020193446A1 (en) 2002-12-19
DE69829966T2 (de) 2006-02-09
JP3930056B2 (ja) 2007-06-13
CN1977837B (zh) 2010-12-08
CA2292388A1 (en) 1998-11-19
SK286766B6 (sk) 2009-05-07
AU750041B2 (en) 2002-07-11
ATE304350T1 (de) 2005-09-15
IL164568A (en) 2010-05-31
EA199901026A1 (ru) 2000-08-28
PT1464639E (pt) 2007-06-15
EA199901027A1 (ru) 2000-06-26
TR199902802T2 (xx) 2000-04-21
DE69831566T2 (de) 2006-06-14
KR20010012504A (ko) 2001-02-15
US20020177717A1 (en) 2002-11-28
EP0981343A2 (en) 2000-03-01
KR20010012503A (ko) 2001-02-15
US6617352B2 (en) 2003-09-09
NO316221B1 (no) 2003-12-29
IL132797A0 (en) 2001-03-19
ES2241139T3 (es) 2005-10-16
CN101284808A (zh) 2008-10-15
EA009370B1 (ru) 2007-12-28
CA2428130A1 (en) 1998-11-19
CY1107645T1 (el) 2013-04-18
IL132798A (en) 2006-12-31
NO20032254D0 (no) 2003-05-19
US7375252B2 (en) 2008-05-20
KR20080066885A (ko) 2008-07-16
US6121319A (en) 2000-09-19
US6548699B1 (en) 2003-04-15
CZ301183B6 (cs) 2009-12-02
NO319855B1 (no) 2005-09-26
CZ301985B6 (cs) 2010-08-25
HU226611B1 (en) 2009-04-28
KR20070007207A (ko) 2007-01-12
US6147250A (en) 2000-11-14
IL178072A (en) 2010-12-30
NO995543D0 (no) 1999-11-12
AU7571198A (en) 1998-12-08
AU747801C (en) 2003-01-30
JP2006232848A (ja) 2006-09-07
EP0981343B1 (en) 2005-09-14
ID23877A (id) 2000-05-25
WO1998051662A3 (en) 2000-03-02
EA200601059A1 (ru) 2007-02-27
NO995544D0 (no) 1999-11-12
CA2292388C (en) 2004-07-20
EA200800375A1 (ru) 2008-06-30
AU7485198A (en) 1998-12-08
CZ9904023A3 (cs) 2001-07-11
EA200500249A1 (ru) 2005-06-30
CN1977837A (zh) 2007-06-13
ES2248901T3 (es) 2006-03-16
NO327603B1 (no) 2009-08-31
KR100919883B1 (ko) 2009-09-30
KR100882335B1 (ko) 2009-02-11
CZ9904024A3 (cs) 2001-10-17
CZ301313B6 (cs) 2010-01-13
IL132798A0 (en) 2001-03-19
ATE356113T1 (de) 2007-03-15
HUP0004230A2 (hu) 2001-06-28
JP2001524986A (ja) 2001-12-04
US6828447B2 (en) 2004-12-07
HUP0004592A3 (en) 2001-12-28
AU747801B2 (en) 2002-05-23
HK1025947A1 (en) 2000-12-01
BR9809793A (pt) 2000-06-27
KR20070008725A (ko) 2007-01-17
CN1200704C (zh) 2005-05-11
EA012847B1 (ru) 2009-12-30
HUP0004230A3 (en) 2001-12-28
PL336788A1 (en) 2000-07-17
CN1275596C (zh) 2006-09-20
DE69837295D1 (de) 2007-04-19
IL178072A0 (en) 2006-12-31
EP0994853B1 (en) 2005-04-27
ID29158A (id) 2001-08-02
NO995543L (no) 2000-01-10
IL175130A (en) 2009-02-11
CN1287783C (zh) 2006-12-06
US20050090487A1 (en) 2005-04-28
US6602914B2 (en) 2003-08-05
NZ501069A (en) 2000-07-28

Similar Documents

Publication Publication Date Title
BR9809819A (pt) Compostos e métodos para a inibição da expressão de vcam-1
FI971974A0 (fi) Tienopyridiini- tai tienopyrimidiinijohdannaiset ja niiden käyttö
ECSP034441A (es) Tratamiento de depositos de sulfuro de hierro
BR9916567A (pt) Combinações de inibidores do transporte ácido dabile ileal e derivados do ácido nicotìnico paraindicações cardiovasculares
BR9811099A (pt) Inibidores de urocinase
SE9802333D0 (sv) Novel combination
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
BR9812753A (pt) Combinação farmacêutica, uso da mesma, processo para tratamento de uma doença inflamatória, e, composição farmacêutica
TR199801151T2 (xx) Trombin inhibit�r� �n ila�lar.
PT1077940E (pt) 4-fenilpiperidinas novas para o tratamento de dermatoses pruriginosas
YU44398A (sh) Derivati supstituisanog benzensulfonamida kao prolekovi cox-2 inhibitora
BR0114913A (pt) Inibidores de metaloproteinase de espiro-pirimidina-2,4,6-triona
EA200401183A1 (ru) Применение ингибиторов il-18 в качестве диагностического маркера
BR9808140A (pt) Formulação unitária
BR9907655A (pt) Derivados de ácido di-hidróxi-hexanóico
BR9612283A (pt) Composição para o tratamento de manchas em peças de roupa e métodos de tratamento
SE9801494D0 (sv) Novel use
BR0309435A (pt) Combinação farmacêutica para o tratamento de hiperplasia prostática benigna ou para a prevenção a longo prazo de retenção urinária aguda
MX9703944A (es) Metodo para usar derivados de triaril-etileno en el tratamiento y prevencion de osteoporosis.
IS5951A (is) 5HT1 mótlyf fyrir meðferð gegn þunglyndi
BR9810616A (pt) Inibidores de farnesil transferase em combinação com inibidores de hmg coa redutase para o tratamento do cancer
BR0108980A (pt) Aplicação e formulação farmacêuticas compreendendo inibidor de reabsorção de norepinefrina
BG100248A (bg) Инхибитори на скваленсинтетаза
PT1263421E (pt) Avasimibe, o inibidor duplo da sintese de ester de colesterilo e de ester ceroso, para o tratamento de disturbios da glandula sebacea
PT1187612E (pt) Utilizacao do riluzole para o tratamento da esclerose multipla

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA ( ARTIGO 8O COMBINADO COM ARTIGO 13 DA LPI )

B12B Appeal against refusal [chapter 12.2 patent gazette]